In March, the University of Southampton and drug development company Synairgen began clinical tests of SNG001, a special, inhaled formulation of the naturally occurring antiviral protein interferon beta 1a on patients with COVID-19. This new phase follows receipt of the necessary approvals to expand from the original 100 patients, to include enrolling an additional 120 patients in the home environment. MedicalXpress
Wednesday, May 27, 2020
University-led COVID19 drug trial expands into home testing
In March, the University of Southampton and drug development company Synairgen began clinical tests of SNG001, a special, inhaled formulation of the naturally occurring antiviral protein interferon beta 1a on patients with COVID-19. This new phase follows receipt of the necessary approvals to expand from the original 100 patients, to include enrolling an additional 120 patients in the home environment. MedicalXpress
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment